Innate Pharma SA-Spons ADRIPHA
13F holders, Q1 2026 (March 31)9holders −2
1new positions
3sold out
1famous investor
$1.28avg. 13F price*
At the end of Q1 2026, 9 institutions reported holding Innate Pharma SA-Spons ADR (IPHA) in their 13F filings, down 2 from Q4 2025. 1 opened new positions and 3 sold out. The largest holders were Lion Point Capital, LP ($104K), Morgan Stanley ($56K) and Jane Street Group, LLC ($56K). One famous investor held it Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Innate Pharma SA-Spons ADR
- CUSIP
- 45781K204
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $3 |
| Exits | 3 | $50K |
All 13F filers, Q4 2025 → Q1 2026: 2 shares bought and 92,324 shares sold, net −92,322 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Lion Point Capital, LP | 0.62% | No change | 81,151 | $104K |
| Morgan Stanley | 0.00% | Reduce -6.2% | 43,524 | $56K |
| Jane Street Group, LLC | 0.00% | Reduce -53.3% | 43,365 | $56K |
| Millennium Management | 0.00% | Reduce -50.4% | 10,064 | $13K |
| Rhumbline Advisers | 0.00% | Reduce -9.0% | 4,734 | $6K |
| UBS Group AG | 0.00% | Reduce -9.1% | 861 | $1K |
| GAMMA Investing LLC | 0.00% | Reduce -77.6% | 240 | $307 |
| Farther Finance Advisors, LLC | 0.00% | No change | 10 | $14 |
| Caitong International Asset Management Co., Ltd | 0.00% | New | 2 | $3 |
"% of holder's portfolio" is IPHA's weight in each manager's 13F, not the share of Innate Pharma SA-Spons ADR the manager owns.